Company: PCRX
Filing Date: 2025-02-27
Form Type: 10-K
Source: 0001396814-25-000041
Chunk: 294

Company: Pacira BioSciences, Inc.
Filing Date: 2025-02-27
Form: 10-K
Item: Item 8
Chunk 294
---
,811 — — 2,811 Stock-based compensation— — — — 47,895 — — 47,895 Other comprehensive income (Note 12)— — — — — — 627 627 Net income— — — — — 41,955 — 41,955 Balance at December 31, 202346,481 — 46 — 976,633 (106,796)247 870,130 Vested restricted stock units501 — 1 — — — — 1 Common stock withheld for employee withholding tax liabilities on vested restricted stock units(19)— — — (491)— — (491)Common stock issued under employee stock purchase plan115 — — — 2,298 — — 2,298 Stock-based compensation— — — — 51,171 — — 51,171 Purchase of treasury stock, inclusive of excise tax— (837)— (25,121)— — — (25,121)Purchase of capped call transaction, net of tax— — — — (20,176)— — (20,176)Other comprehensive income (Note 12)— — — — — — 96 96 Net loss— — — — — (99,560)— (99,560)Balance at December 31, 202447,078 (837)$47 $(25,121)$1,009,435 $(206,356)$343 $778,348 

See accompanying notes to consolidated financial statements.

Pacira BioSciences, Inc.  |  2024 Annual Report on Form 10-K  |  Page F-8

PACIRA BIOSCIENCES, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands) Year Ended December 31, 202420232022Operating activities:   Net (loss) income$(99,560)$41,955 $15,909 Adjustments to reconcile net (loss) income to net cash provided by operating activities:   Goodwill impairment163,243 — — Loss on lease terminations2,165 — — Deferred taxes20,621 15,615